# Junta clínica — PT-pseudo_4b950525e6a8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4b950525e6a8",
  "pid": "PT-pseudo_4b950525e6a8",
  "task": 1,
  "psa": 19.0,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.37,
  "psav": 2.0,
  "psap": 18.4,
  "vol": 51.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.88825184,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "80 kg",
    "height": "175 cm",
    "bmi": "26.1",
    "bp": "134/81 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2022)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Mar 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Widowed",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.44
  uncertainty  +/- 0.15 (95% CI 0.14-0.73); among patients it cannot tell apart the outcome was 0.99 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-based pathway based on PI-RADS score, PSA density, and prior biopsy status. It states that patients with a PI-RADS score of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy) could forgo biopsy while others underwent combined systematic and MRI-targeted biopsy.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not settled because it fails to account for the patient's PI-RADS 5 score and the prior positive biopsy status. The guideline's decision hinges on a risk-based matrix that the classifier could not read, specifically the PI-RADS 5 score, which is a high-risk factor that overrides the low-risk profile suggested by other variables.

WHAT WE STILL NEED
The mpMRI prose - PI-RADS 5 mandates a high-risk assessment, which is a variable the classifier could not weigh against the guideline's risk matrix.
Prior biopsy status - The patient has a prior positive biopsy, which is a critical factor that the classifier failed to incorporate into its decision.
Laboratory value - The PSA density of 0.37 ng/mL² is a variable that the guideline uses in its risk-based matrix to determine the appropriate pathway.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on integrating the high-risk PI-RADS 5 finding and the prior positive biopsy status into the EAU risk-based pathway.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose regarding lesion characteristics and extension.
  psa_trend (get_psa_trend) -> Determine the PSA trend to assess the rate of change.
  previous_notes (get_previous_notes) -> Determine the management context, including what was agreed with the patient regarding surveillance.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the lesion size, zone, and extraprostatic extension?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. Dropped 1 question(s) that asked for a value already printed on the panel: "How does the prior positive biopsy status interact with the PI-RADS 5 score in the EAU risk-based matrix?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
Radiology report: The mpMRI prose states there is a PI-RADS 5 lesion in the left peripheral zone, measuring ~18 mm, with intense DWI restriction and prompt, localized enhancement.
PSA trend: The PSA trend shows values of 2.1 ng/mL/yr from Jul 2023 to 6.3 ng/mL/yr, and then to 19.0 ng/mL at Mar 2025.
Previous notes: The previous notes indicate that a transrectal biopsy was conducted on 04 July 2024, yielding a diagnosis of Gleason 4+4 carcinoma.

WHAT I DID NOT OPEN
I did not open the laboratory results because the moderator did not specify which question regarding free-PSA fraction, infection, or prostatitis was to be answered.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 mandates a high-risk assessment.
- Previous notes: The prior positive biopsy status is a critical factor.
AGAINST sampling this patient now:
- Previous notes: The prior biopsy yielded a Gleason 4+4 carcinoma, which is a known diagnosis.

WHERE THIS LEANS
The findings strongly suggest that the high-risk imaging and prior positive biopsy status necessitate further action beyond deferral.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—have answered the moderator's question Q1 regarding the mpMRI prose, as the registrar reported that the report states there is a PI-RADS 5 lesion in the left peripheral zone, measuring ~18 mm, with intense DWI restriction and prompt, localized enhancement.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-EAU's reasoning that the PI-RADS 5 score mandates a high-risk assessment, which the classifier failed to weigh against the guideline's risk matrix.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the lesion size, zone, and extraprostatic extension? Answered by the REGISTRAR with the radiology_report, stating a PI-RADS 5 lesion in the left peripheral zone, measuring ~18 mm, with intense DWI restriction and prompt, localized enhancement.
Q2. What does the psa_trend state regarding the PSA trend to assess the rate of change? Answered by the REGISTRAR with the psa_trend, showing values of 2.1 ng/mL/yr from Jul 2023 to 6.3 ng/mL/yr, and then to 19.0 ng/mL at Mar 2025.
Q3. What does the previous_notes state regarding the management context, including what was agreed with the patient regarding surveillance? Answered by the REGISTRAR with the previous_notes, indicating a transrectal biopsy on 04 July 2024 yielding a Gleason 4+4 carcinoma.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 score, which mandates a high-risk assessment, and the prior positive biopsy status, which is a critical factor in the EAU risk-based pathway. The PSA trend also matters because it shows a significant rate of change leading to the current high PSA. The guideline does not support the classifier's suggestion of "NO BIOPSY" because the PI-RADS 5 score overrides low-risk factors.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy to further characterize the high-risk lesion identified by the mpMRI and to assess the biological significance of the prior positive biopsy result in the context of the current high PSA.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy yielding a Gleason 4+4 diagnosis, the high PI-RADS 5 score and the significant PSA velocity necessitate further characterization. The retrieved mpMRI report detailing a PI-RADS 5 lesion and the PSA trend showing a rate of change strongly support proceeding with a biopsy to assess the biological significance of the findings.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=important, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
